Trial Profile
Phase II Trial of LBH589 (Panobinostat) in Relapsed or Relapsed and Refractory Waldenstrom's Macroglobulinemia.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Panobinostat (Primary)
- Indications Waldenstrom's macroglobulinaemia
- Focus Therapeutic Use
- 10 Jan 2021 Status changed from active, no longer recruiting to completed.
- 27 Jan 2020 Planned End Date changed from 1 Dec 2021 to 1 Feb 2020.
- 27 Jan 2020 Planned primary completion date changed from 1 Jul 2021 to 1 Feb 2020.